Premium
Expression of regenerating gene I in gastric adenocarcinomas
Author(s) -
Dhar Dipok Kumar,
Udagawa Jun,
Ishihara Shunji,
Otani Hiroki,
Kinoshita Yoshikazu,
Takasawa Shin,
Okamoto Hiroshi,
Kubota Hirofumi,
Fujii Toshiyuki,
Tachibana Mitsuo,
Nagasue Naofumi
Publication year - 2004
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.20097
Subject(s) - medicine , immunohistochemistry , cancer , in situ hybridization , lymph , adenocarcinoma , pathology , gene expression , oncology , cancer research , gene , biology , biochemistry
BACKGROUND Regenerating gene I (REG) was identified as a growth factor for pancreatic islet beta cells. Enhanced REG expression was observed during the healing of gastric mucosa. REG expression was observed in various tumors including gastric carcinoma, but to the authors' knowledge, the correlation between REG expression and clinicopathologic characteristics and patient prognosis have not been evaluated. METHODS The REG messenger RNA level was analyzed by Northern blot analysis and localization was performed by in situ hybridization and immunohistochemistry in gastric adenocarcinoma specimens. The correlations between REG expression and clinicopathologic features and survival of the patients were analyzed. RESULTS Of the 68 patients studied, 24 (35%) were positive for REG. There was a significant consistency in the intensity and localization of REG transcript and protein expressions. REG expression was enhanced in advanced T classification tumors and in tumors that were not well differentiated. A significant number of metastatic lymph nodes were present in REG‐positive tumors. Overall and disease‐free survival were found to be poor for patients with REG‐positive tumors. REG expression was reported to be an independent predictor of overall patient survival. CONCLUSIONS Determination of REG expression may help to identify aggressive gastric tumors and to tailor appropriate therapy for patients with REG‐positive tumors. Cancer 2004. © 2004 American Cancer Society.